



Ex-factory price (excl. VAT)  
OPDIVO® 40 mg € 588,80 YERVOY® 50 mg € 4.250,00  
OPDIVO® 100 mg € 1.472,00 YERVOY® 200 mg € 17.000,00

Bristol-Myers Squibb is happy to announce the extension of reimbursement of OPDIVO® (nivolumab) as of 1st of January 2017 in the following indications<sup>1</sup>:

- ✓ the treatment of locally advanced or metastatic **non-small cell lung cancer (NSCLC)** after prior chemotherapy in adults as monotherapy
- ✓ the treatment of advanced **renal cell carcinoma (RCC)** after prior therapy in adults as monotherapy
- ✓ the treatment of advanced (unresectable or metastatic) **melanoma** in adults, as monotherapy or in combination with Yervoy®
- ✓ the treatment of adult patients with relapsed or refractory **classical Hodgkin lymphoma (cHL)** after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin as monotherapy

OPDIVO® in monotherapy is the Only Anti-PD-1 Approved and Reimbursed in Multiple Cancer Types Based on **Superior Overall Survival** shown in 4 phase-III studies at the approved dose of 3mg/kg every 2 weeks<sup>1</sup>:



OPDIVO + YERVOY Regimen is the First and Only Approved and Reimbursed **Combination** of Immune Checkpoint Inhibitors with Proven **Superior Efficacy** in 1st Line Advanced Melanoma<sup>\*\*</sup>

The reimbursement request for both OPDIVO® and YERVOY® should be introduced via the e-health platform.

In case of questions, don't hesitate to contact us at [Immuno-Oncology@bms.com](mailto:Immuno-Oncology@bms.com)

The I-O team of Bristol-Myers Squibb

[www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/003985/WC500189765.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf)

\* 1. Opdivo smpc. 2. Robert et al. NEJM 2015;372:320-30. 3. Brahmer et al. NEJM 2015;373:123-35. 4. Borghaei et al. NEJM 2015;373:1627-39. 5. Motzer et al. NEJM 2015;373:1803-13.

\*\* vs Yervoy®